Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy males or females between, and including, 12 and 18 years of age at the time of the first vaccination.~* Female subjects must be of non-childbearing potential.~Exclusion Criteria:~* Previous vaccination against or history of meningococcal B or C, or hepatitis A disease or exposure to meningococcal B disease within last year.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.~* Family history of congenital or hereditary immunodeficiency.~* History of any neurologic disorders or seizures.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).